Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Clinical trial NCT03598244 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03598244
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Diffuse Intrinsic Pontine Glioma Recurrent Malignant Glioma Recurrent Medulloblastoma Recurrent Primary Central Nervous System Neoplasm Refractory Diffuse Intrinsic Pontine Glioma Refractory Malignant Glioma Refractory Medulloblastoma Refractory Primary Central Nervous System Neoplasm

Start date: 2018-11-27
Primary completion: 2026-04-22
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.